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In Huntington’s disease (HD), the mutant huntingtin
protein is ubiquitously expressed. The disease was
considered to be limited to the basal ganglia, but
recent studies have suggested a more widespread
pathology involving hypothalamic dysfunction. Here
we tested the hypothesis that expression of mutant
huntingtin in the hypothalamus causes metabolic
abnormalities. First, we showed that bacterial artifi-
cial chromosome-mediated transgenic HD (BACHD)
mice developed impaired glucose metabolism and
pronounced insulin and leptin resistance. Selective
hypothalamic expression of a short fragment of
mutant huntingtin using adeno-associated viral
vectors was sufficient to recapitulate these meta-
bolic disturbances. Finally, selective hypothalamic
inactivation of the mutant gene prevented the devel-
opment of the metabolic phenotype in BACHD mice.
Our findings establish a causal link between mutant
huntingtin expression in the hypothalamus and
metabolic dysfunction, and indicate that metabolic
parameters are powerful readouts to assess thera-
pies aimed at correcting dysfunction in HD by
silencing huntingtin expression in the brain.
INTRODUCTION
The pathogenic process in the neurodegenerative and fatal Hun-
tington’s disease (HD) is still not fully known despite intense
research since the identification of the disease causing CAG
repeat expansion in the huntingtin (htt) gene (HDCRG, 1993;
Imarisio et al., 2008). HD is characterized by extensive basal
ganglia pathology and the accumulation of neuronal inclusions
formed by ubiquitinated misfolded proteins (DiFiglia et al.,
1997). Although the normal function of htt is not fully known,
mutant htt expression has been suggested to lead to transcrip-
tional dysregulation (Imarisio et al., 2008). As the wild-type
(WT) and mutant forms of huntingtin are ubiquitously expressed,428 Cell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc.it is possible that pathological loss-of-function and gain-of-func-
tion effects outside the basal ganglia play a role in the pathogen-
esis of HD.
The clinical diagnosis of HD has so far been determined by the
presence of overt motor dysfunction (Phillips et al., 2008). Never-
theless, it is now well recognized that nonmotor symptoms and
signs begin several years earlier. These include neuroendocrine
disturbances such as insulin resistance (Lalic et al., 2008), which
has been recapitulated in a number of animal models of HD
(Hult et al., 2010). Emerging studies show that insulin action
specifically in hypothalamic neurons is important for energy
homeostasis (Belgardt et al., 2009). The extent of hypothalamic
involvement in HD is not fully known; however, changes in gray
matter signals, microglia activation, and orexin (also known as
hypocretin) loss have recently been described in this area using
MRI, PET, and postmortem analyses of HD patients (Aziz et al.,
2008; Douaud et al., 2006; Gabery et al., 2010; Kassubek
et al., 2004; Petersen et al., 2005; Politis et al., 2008; Soneson
et al., 2010). Orexin is a neuropeptide selectively expressed in
the hypothalamus, which plays an important role in the regulation
of metabolism (de Lecea et al., 1998; Sakurai et al., 1998).
Although cachexia is a common sign in end-stage HD, increased
appetite and caloric intake have been found in individuals at risk
for or in early stages of the disease (Marder et al., 2009; Mochel
et al., 2007; Trejo et al., 2004). Interestingly, transgenic mice
expressing full-length htt either by a yeast artificial chromosome
(YAC) or a bacterial artificial chromosome (BAC) that resemble
early clinical HD display increased body weight (Gray et al.,
2008; Van Raamsdonk et al., 2006). Transgenic mice expressing
a short fragment of mutant htt resemble late-stage clinical HD
and display increased fat accumulation and insulin resistance
despite weight loss (Bjorkqvist et al., 2006; Li et al., 2003;
Mangiarini et al., 1996; Martin et al., 2009; Phan et al., 2009;
Weydt et al., 2006). These findings indicate that pathogenic
effects in regions involved in the control of metabolism may be
affected in HD.
Based on the notion that hypothalamic changes may induce
increased appetite, insulin resistance, and body fat accumula-
tion, we hypothesized that hypothalamic expression of mutant
htt could cause this part of the metabolic phenotype in HD. By
using viral vector techniques, we have shown that the metabolic
abnormalities in the BACHD mice were fully recapitulated by
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Figure 1. Metabolic Profile of BACHD Mice
(A) Both female and male BACHD mice displayed significantly higher body
weight than their WT littermates already at 2 months of age (n = 9–17/sex and
genotype and age; *p < 0.005).
(B) Increased body fat as assessedwith DEXAwas found in BACHD females at
all times (n = 4–13/sex and genotype and age; *p < 0.01).
(C) Increased food intake was present both at 2 and 4 months of age
in BACHD mice compared to WT mice (n = 4–8/sex and genotype and age;
*p < 0.05).
(D) BACHD females at 4 months of age had a reduced respiratory exchange
ratio (RER) compared to WT mice (*p < 0.05) but no altered oxygen
consumption (n = 6/genotype).
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Ctargeted expression of mutant htt in the hypothalamus of WT
mice, and could be reversed by selective silencing in the
hypothalamus.RESULTS
BACHD Mice Develop Metabolic Abnormalities
The BACHD mouse is a full-length mutant htt model with 97Q
(Gray et al., 2008). As previously reported, we found that both
female and male BACHD mice displayed a significantly
increased body weight compared to their WT littermates already
at 2 months of age and that this difference increased over time
(Figure 1A) (Gray et al., 2008). The aggravated body weight
was partly due to an increase in body fat as assessed using
dual energy X-ray absorptiometry (DEXA; Figure 1B), which
was most prominent in female mice. This was further confirmed
by increased weight of both white and brown adipose tissues in
female BACHD mice compared to WT mice (see Table S1 avail-
able online).
Obesity can be the result of reduced activity, increased food
intake, a reduced metabolic rate, or a combination of these
factors. BACHD mice did not display reduced general activity
in the open field at 4 months of age, a time point when they
were already significantly obese (total line crossings/30 min,
2660 ± 150 in BACHD versus 2550 ± 120 inWTmice; n = 8/geno-
type; n.s.). However, already at 2 months of age, both male and
female BACHD mice displayed a significantly higher food intake
as compared to WT mice, and this difference persisted at
4 months of age (Figure 1C). When the metabolic rate was
assessed using indirect calorimetry, female BACHD mice were
found to have similar oxygen consumption as WT littermates;
however, the respiratory quote was lower, indicating an
obesity-induced compensatory increase in lipid oxidation (Fig-
ure 1D). Taken together, these data showed that BACHD mice
developed obesity as a result of chronically increased food
intake.
Next, we sought to determine which endocrine abnormalities
accompanied the obese phenotype. Female BACHD mice dis-
played significantly increased basal glucose levels (10.03 ±
0.21 mmol/l; n = 6) compared to WT mice (9.05 ± 0.35; n = 6)
(p < 0.05). BACHDmice also showed impaired glucose tolerance
and insulin resistance in a glucose tolerance test (GTT) and
insulin tolerance test (ITT), respectively, as well as increased
basal insulin levels (Figures 1E–1G, Table S2). Leptin is one of
the key regulators of body weight that normally acts on the hypo-
thalamus to reduce food intake through intracellular signaling
involving phosphorylation of Stat3 (p-Stat3). We found that
serum levels of leptin were severely elevated in BACHD mice,
indicative of leptin resistance (Table S2). Reduced leptin sensi-
tivity in the CNS of BACHD was confirmed by reduced p-Stat3
activation in the hypothalamus after an i.p. injection of leptin in(E–G) A pathological response in the GTT and ITT was found in BACHD
compared to WT mice (n = 6/genotype; *p < 0.001). Open labels indicate WT,
black labels indicate BACHD, circles indicate females, and squares indicate
males. All data are expressed as means ± SEM. *, significant difference to WT
mice of the same sex (see the Supplemental Statistical Results in the
Supplemental Information). See also Figure S1, Table S1, and Table S2.
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Figure 2. Hypothalamic Expression Induced by Adeno-Associated
Viral Vectors
(A) Representative photograph of a brain section stained for GFP 12 weeks
postinjection demonstrating targeted expression in the hypothalamus.
(B) Numbers of GFP-positive cells in the hypothalamus were assessed using
stereology (n = 4/time point).
(C–E) Representative images showing huntingtin (htt) inclusions after expres-
sion of htt853-79Q.
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430 Cell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc.BACHDmice compared toWTmice (Figure S1). Other peripheral
factors related to appetite control and adipose tissue metabo-
lism such as interleukin 6 (IL-6) and ghrelin, as well as nonester-
ified free fatty acids (NEFAs) or triglycerides, were not altered in
serum (Table S2). Cholesterol and adiponectin levels were
increased in female BACHD mice (Table S2).TargetedHypothalamic Expression of htt853-79QLeads
to Metabolic Disturbances
To test the hypothesis that hypothalamic expression of mutant
htt was responsible for the development of metabolic distur-
bances in BACHD mice, we used recombinant adeno-associ-
ated viral vectors of serotype 5 (rAAV5) to selectively express
a large N-terminal fragment of the mutant htt protein in the hypo-
thalamic region of adult mice of the FVB/N strain. In order to illus-
trate the effectiveness of gene transfer to the hypothalamus
using this viral vector serotype, we first injected mice with
rAAV5 vectors expressing the green fluorescent protein (GFP)
under the control of the neuronal-specific synapsin promotor.
Following an injection of 0.5 ml rAAV5-GFP vectors in a single
deposit in the hypothalamus, we targeted a number of key hypo-
thalamic neuronal populations expressing metabolism-regu-
lating neuropeptides such as orexin, melanin-concentrating
hormone (MCH), cocaine and amphetamine regulating neuro-
peptide (CART), proopiomelanocortin (POMC), vasopressin,
and oxytocin as illustrated using confocal microscopy with anti-
bodies against GFP and the different neuropeptides (Figures
S2A–S2F). The GFP-positive cells were indeed distributed to
cover 87% ± 7% of the hypothalamus region (n = 12). We
obtained a stable expression of GFP in an average of about
23,800–46,000 cells at 6, 12, and 18weeks postinjection (Figures
2A and 2B). We then used the same rAAV5 vector design to
express the first 853 amino acids of htt with either 18Q (rAAV5-
htt853-18Q; the normal variant that served as a control) or 79Q
(rAAV5-htt853-79Q; disease causing mutant protein) under the
synapsin promotor in the hypothalamus of 2-month-old WT
mice. Uninjected mice constituted a second control group. A
subgroup of unilaterally injected mice was processed for neuro-
pathological analyses. In the htt853-79Q group, cells containing
intracellular htt inclusions were detected already at 6 weeks
postinjection (2894 ± 142 cells; n = 4; Figures 2C, 2C0, and
2G). The numbers of htt inclusion-containing cells were esti-
mated at 18,503 ± 7,173 and 12,055 ± 1,152 cells at 12 and
18 weeks postinjection, respectively (n = 4/group; Figures 2D,
D0, 2E, 2E0, and 2G). Similar numbers of cells were found to
express ubiquitinated inclusions in the hypothalamic region as
assessed with stereology (Figure 2H). Only diffuse cytosolic htt
staining was present after injections of the control htt fragment
(Figures 2F and 2F0), and no ubiquitinated inclusions were
detected. Stereological assessment and morphological analysis
of numbers of cells using Nissl stain revealed no overt loss of(F) Diffuse cytoplasmic htt staining was seen after expression of htt853-18Q
(here shown at 18 weeks postinjection).
(G and H) Numbers of cells with htt- and ubiquitin-labeled inclusions in the
hypothalamus were assessed using stereology 6, 12, and 18 weeks after
injections of 79Q (n = 4/time point). All data are expressed as means ± SEM.
Scale bar in (A), 500 mm; in (C), 100 mmand applies to (C) –(F); in (F0), 20 mmand
applies to (C0)–(F0). See also Figure S2 and Table S3.
Table 1. Metabolic Candidate Genes Analyzed Using qRT-PCR
Candidate Gene
18Q (Percent
of Control)
79Q (Percent
of Control)
Statistical
Differences
Receptors
Dopamine D2
receptor
85 ± 12 85 ± 6
Serotonin 2A
receptor
94 ± 6 92 ± 8
Serotonin 2C
receptor
115 ± 6 109 ± 14
GABA receptor 85 ± 3 83 ± 4
Insulin receptor 104 ± 2 113 ± 12
Leptin receptor 93 ± 5 102 ± 12
Melanocortin
4 receptor
102 ± 8 94 ± 10
Orexin 1 receptor 66 ± 4* 78 ± 4* *p < 0.05 to C
Orexin 2 receptor 85 ± 7 93 ± 5
BDNF, IL-6, ER Stress
BDNF 101 ± 3 107 ± 6
IL-6 138 ± 13 98 ± 15
XBP1-S 111 ± 4 109 ± 15
CHOP 140 ± 9 117 ± 17
Arcuate Nucleus
POMC 97 ± 10 100 ± 21
AgRP 109 ± 8 81 ± 14
NPY 118 ± 7 84 ± 13
PVN
Brn2 101 ± 3 93 ± 2
Sim1 89 ± 4 93 ± 1
Vasopressin 77 ± 3* 70 ± 7* *p < 0.05 to C
Oxytocin 139 ± 8 87 ± 7* *p < 0.05 to 18Q
CRH 113 ± 8 82 ± 7* *p < 0.05 to 18Q
Somatostatin 89 ± 4 64 ± 3* *p < 0.05 to 18Q, C
TRH 92 ± 5 63 ± 2* *p < 0.05 to 18Q, C
The data are expressed as mean ± SEM of the expression levels in mice
4 weeks after injection of rAAV5-htt853-79Q or 18Q bilaterally in the
hypothalamus in percentage of the levels in uninjected controls (n = 6–8/
group). Statistical analyses were performed using one-way ANOVA
followed by post hoc tests. BDNF, brain-derived neurotrophic factor;
CHOP, C/EBO homologous protein; XBP1 s, X-box-binding protein-1,
spliced version.
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injected with rAAV-htt853-79Q (Table S3). The injections of viral
vectors in the hypothalamus did not lead to any immune
response beyond a limited activation immediately around the
injection site as illustrated with the microglia marker Iba1 (Fig-
ure S3). Similarly, hypothalamic mRNA levels of IL6 were not
different between the groups, and serum levels of IL-6, tumor
necrosis factor (TNF)-a, IL-1b, and interferon (IFN)-g were very
low or undetectable in all animals (Table 1, Table S4).
Mice with hypothalamic injections were followed with assess-
ments of body weight. We found that mice expressing the
htt853-79Q variant displayed a significantly higher body weight
already 4weeks postinjection (Figure 3A). At 18weeks postinjec-Ction, mice with htt853-79Q weighed 43.1 ± 3.7 g. Control vector
injected mice weighed only 30.0 ± 2.0 g, which was not different
from the uninjectedmice at the same age (28.3 ± 0.9 g). The body
weight gain was not due to increased general growth in the
htt853-79Q group, as the snout-to-anus length was similar in
all groups. Instead, the increased body weight in the htt853-
79Q group was accompanied with a significantly higher body
fat percentage as assessed using DEXA (Figures 3B and 3C).
This was further confirmed by increased weight of white and
brown adipose tissues at 18 weeks postinjection (Table S5).
Interestingly, although unilateral htt853-79Q expression did not
lead to the same extreme phenotype as bilateral injections, the
unilaterally injected mice reached to 36.8 ± 3.2 g at 18 weeks
postinjection, representing a 30% increase over the uninjected
mice.
As a likely consequence of the established obesity in the later
stages, mice expressing htt853-79Q displayed significantly
reduced oxygen consumption, indicative of a reducedmetabolic
rate (Figure 3D). These mice also displayed a pathological GTT
and ITT, indicative of impaired glucose tolerance and insulin
resistance (Figures 3E–3G). Hence, hypothalamic expression
of a large fragment of the htt protein with an expanded polyglut-
amine led to rapid body weight gain with accompanying
systemic insulin resistance.
To determine if hyperphagia or reduced motor activity caused
the first weight gain in the htt853-79Q group, we analyzed
the mice 2–4 weeks postinjection. General motor activity as
assessed over 24 hr was not altered in mice with the htt853-
79Q variant at that time (Figure 3H), although explorative motor
activity was reduced 18 weeks postinjection in both 79Q and
18Q (total line crossings/10 min, 168 ± 45 in 79Q; 489 ± 37 in
18Q; 673 ± 36 in uninjected controls; n = 5–8/group, one-factor
analysis of variance [ANOVA] followed by Tukey’s HSD post hoc
test p < 0.05 between all groups). Importantly, food intake was
significantly increased at 2 and 4 weeks of age in mice with the
79Q variant compared to the other two groups, indicating that
hypothalamic expression of a mutant htt fragment induced
hyperphagia (Figure 3I). Quantitative RT-PCR analysis confirmed
similar mRNA levels of the two htt fragments at this stage (fold
expression in relation to mRNA levels for the housekeeping
gene HPRT, 1.22 ± 0.28 for 79Q and 1.00 ± 0.21 for 18Q, n =
6–8/group, Student’s t test p = 0.52, n.s.). Leptin levels were
significantly increased in mice with 79Q compared to 18Q both
4 and 18 weeks postinjection (Figure 3J). Basal insulin levels
were normal in all groups 4 weeks postinjection but significantly
increased 18 weeks postinjection in the 79Q variant (Figure 3K).
Taken together, expression of the htt853-79Q variant specifically
in hypothalamic neurons elevated food intake, leading to overt
obesity as well as leptin and insulin resistance.
Mutant htt Induces Hyperphagia and Obesity
Independent of Fragment Length
Transgenic mice with ubiquitous expression of full-length mutant
htt gain weight, whereas mice expressing short fragments of
mutant htt lose weight despite increased fat accumulation and
insulin resistance (Hult et al., 2010). As part of this study, we
injected female FVB/N mice with rAAV vectors of a similar titer
expressing either htt853-79Q or a shorter fragment with 171
amino acids expressing 79Q (htt171-79Q) bilaterally into theell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc. 431
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Figure 3. Rapid Onset of Metabolic Disturbances after Hypothalamic Expression of a Mutant htt Fragment
(A) Mice bilaterally injected with rAAV5-htt853-79Q displayed increased body weight already 4 weeks postinjection (n = 13–15/group until 12 weeks, then n = 5–7/
group; *p < 0.05). Increased body fat in the 79Q variant as assessed with DEXA (B) (*p < 0.05), which is illustrated using representative images from the three
groups (C). (D) At 15 weeks after injection of 79Q, the oxygen consumption was reduced (*p < 0.001), but the respiratory exchange ratio was normal (n = 6/
genotype). (E–G) Thesemice also displayed pathological responses in aGTT (also expressed as total amount of glucose during the 120min, *p < 0.001) and an ITT
(*p < 0.05) at 16–18 weeks postinjection, respectively (n = 6/group). (H) General motor activity was not different in 79Q compared to 18Q and uninjected mice 3
and 4 weeks postinjection (n = 6–7/group). (I) Food intake was increased both 2 and 4 weeks postinjection in 79Q (n = 5–8/group) (*p < 0.005). (J) Serum leptin
levels were increased already at 4 weeks postinjection in 79Q compared to 18Q (n = 4–7/group) (*#p < 0.05). (K) Insulin levels were increased in the 79Q variant
18 weeks postinjection (n = 5–7/group) (*p < 0.05). Data are expressed as means ± SEM. *, significant difference between 79Q and other groups. #, significant
difference between 79Q and 18Q (see the Supplemental Statistical Results in the Supplemental Information). See also Figure S3, Table S4, and Table S5.
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Hypothalamic Expression of Mutant Huntingtinhypothalamus. We found that both groups of injected mice
gained equal amounts of body weight and accumulated similar
excess body fat (Figures 4A–4C). The development of obesity
was likely due to the early increase in food intake (Figure 4D),
as reduced motor activity was found only in later stages when
mice were already obese (Figure 4E).
Deletion of Mutant htt in the Hypothalamus in Young
Female BACHDMice Prevents the Metabolic Phenotype
Next, we set out to provide evidence that the development of
obesity was due to hypothalamic dysfunction induced bymutant432 Cell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc.htt in the BACHD mice. This was plausible since the obese
phenotype in BACHD mice was not coupled to massive cell
loss in the hypothalamus, as old BACHD mice did not display
atrophy of this region, general neuronal loss, or microglia activa-
tion (Table S6). For this purpose we took advantage of the fact
that the BACHD mouse was constructed with loxP sites that
enable Cre recombinase (Cre)- mediated excision of mutant htt
exon 1 (Gray et al., 2008). We therefore injected rAAV5 vectors
expressing Cre bilaterally into the hypothalamus of BACHD
(BACHD+Cre) and WT littermates (WT+Cre) either at 2 months
of age (corresponding to the onset of metabolic dysregulation)
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Figure 4. Rapid Onset of Metabolic Disturbances after
Hypothalamic Expression of a Short Mutant htt Fragment
(A) Mice bilaterally injected with rAAV5-htt853-79Q and rAAV5-
htt171-79Q displayed increased body weight 6 weeks post-
injection compared to control mice (n = 9/group) (*p < 0.05).
Increased body fat was found in both 79Q variants compared to
controls as assessed with DEXA (B) (*p < 0.05), which is illustrated
using representative images from the three groups (C). (D) Food
intake was significantly increased both 6 and 18 weeks post-
injection in the htt171-79Q variant compared to controls (n = 9/
group) (*p < 0.05). (E) General motor activity was reduced in both
variants with 79Q at 12 and 18 weeks postinjection (n = 9/group)
(*p < 0.05 compared to control mice). All data are expressed as
means ± SEM (see Supplemental Statistical Results in the
Supplemental Information).
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followed them for 2 months. We found that BACHD+Cre female
mice, in whichmutant htt was deleted at 2months of age, did not
become obese and displayed normal leptin levels at 4 months of
age (Figures 5A and 5B). Insulin levels were also significantly
lower in female BACHD+Cre mice (1.40 ± 0.21 ng/ml) compared
to uninjected female BACHD mice (2.95 ± 0.11 ng/ml; p < 0.05).
Furthermore, targeted deletion of mutant htt normalized food
intake in these mice at 4 months of age (4.6 ± 0.1 g/day in female
BACHD+cre versus 4.2 ± 0.3 g/day in femaleWT + cre; Student’s
t test, n.s.). However, both female and male BACHD mice
injected at 6 months of age remained obese and were not
different than noninjected BACHD mice in body weight or leptin
levels (Figures 5D, 5E, 5G, and 5H). Correct hypothalamic target-
ing in all mice was confirmed by immunohistochemistry for Cre
(Figures 5C, 5F, and 5I). Around 61,900 ± 6,500 cells per side
of the hypothalamus expressed Cre (n = 7), which constitutesCell Metabaround 28% of the total number of neurons in this
area as there are around 218,400 ± 4,962 neurons in
the unilateral hypothalamus. Stereological analysis of
Nissl-stained cells demonstrated that Cre expression
did not cause neuronal loss or gliosis. PCR analysis
confirmed that Cre-mediated excision of mutant htt
occurred in the hypothalamus, but not in the striatum
or the cerebral cortex in BACHD mice injected with
rAAV-Cre in the hypothalamus (Figure 5J).
Metabolic Dysfunction Is Not Associated
with Changes in IGF-1 or HAP-1 Levels
In order to investigate howmutant htt expression in the
hypothalamus led to the development of metabolic
disturbances, we performed a number of analyses. A
recent study had suggested that full-length htt affects
body weight by modulating expression of insulin-like
growth factor-1 (IGF-1) (Pouladi et al., 2010). We also
found that IGF-1 levels were significantly increased in
BACHD mice (345 ± 11 ng/ml) compared to their WT
littermates (286 ± 15 ng/ml). If IGF-1 would be impor-
tant in causing an increase in body weight, then
changes of this factor would be expected to occur
early also after hypothalamic injections of mutant htt
fragments. However, we found that when mice with
bilateral hypothalamic expression of htt853-79Q havestarted to gain weight, mRNA levels of IGF1/or its receptor in
the hypothalamus or serum levels of IGF-1 were not altered
(Figures 6A and 6B). Moreover, at 18 weeks postinjection,
when only mice with 79Q but not 18Q have gainedweight, serum
levels of IGF-1 were increased to a similar extent in both groups
(Figure 6B). A similar increase occurred also in mice with unilat-
eral injections of 79Q and 18Q (Figure 6B). Furthermore, mice
overexpressing a short fragment of mutant htt displayed both
obesity and increased IGF-1 (Figure 6C). Finally, BACHD mice
displayed increased IGF-1 levels in serum even when the meta-
bolic phenotype was prevented by cre-mediated excision, illus-
trating a dissociation between increased IGF-1 and body weight
(Figure 6D). Taken together, our data showed that expression of
different fragment sizes of or full-length htt in the hypothalamus
led to increased IGF-1 levels in serum but that this was indepen-
dent of their effect on body weight. In conclusion, we argue that
IGF-1 is not causally linked to body weight changes in HD mice.olism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc. 433
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Figure 5. Deletion of Mutant htt in the Hypothalamus in Young Female BACHD Mice Prevented the Development of Obesity
(A) Targeted inactivation of mutant htt in the hypothalamus after bilateral injections of rAAV5-Cre prevented the development of obesity in 2-month-old female
BACHDmice (*p < 0.05), which was accompanied with normal leptin levels (B) (*p < 0.005) (n = 4–5/group). No effect of rAAV-Cre injections was found in already
obese female or male BACHD mice (D, E, G, H) (#p < 0.01) (n = 6–7/group). All data are expressed as means ± SEM. Correct targeting of Cre is illustrated here in
both 4- and 8-month-old BACHDmice (C, F, I). PCR analysis confirmed the successful excision of mutant htt in different nuclei in the hypothalamus, but not in the
striatum or cerebral cortex, after hypothalamic expression of Cre in BACHD mice (J). Input control is provided by amplification of the ghrelin gene. LH, lateral
hypothalamus; PVN, paraventricular nucleus; ARC, arcuate nucleus; R. Hypo, remaining tissue in the hypothalamus. Scale bars in (C), (F), and (I) represent 100
mm. *, significant difference to all other groups. #, significant difference between BACHD andWTmice (see Supplemental Statistical Results in the Supplemental
Information). See also Table S6.
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Figure 6. Analysis of IGF-1, HAP-1, and Orexin
(A) mRNA levels of IGF-1 and the IGF-1 receptors were not altered 4 weeks postinjection of rAAV-5 vectors expressing htt853-79Q and htt853-18Q. (B) Serum
levels of IGF-1 were normal in all mice at 4 weeks postinjection but significantly increased in mice with both unilateral and bilateral injections of 79Q and 18Q,
despite the fact that only mice with bilateral injections of 79Q gained weight. (C) Mice with bilateral hypothalamic injections of htt171-79Q displayed significantly
increased IGF-1 serum levels 18 weeks postinjection, showing that different fragments of mutant htt can induce IGF-1 expression. (D) Levels of IGF-1 remained
increased in BACHD mice despite the fact that Cre expression in the hypothalamus at 2 months of age prevented the body weight gain. *p < 0.05 compared to
control, or WT. (E) Representative western blots of HAP-1 (H) and GAPDH (G). (F and G) HAP-1 levels were similar in the hypothalamus of BACHD andWTmice at
2 months (n = 4/group) and in mice with bilateral injections of the htt fragments and controls 4 weeks postinjection (n = 3/group) as assessed using western blots
andwith expression levels of HAP-1 normalized to levels of GAPDH. (H) mRNA levels of orexin were significantly reduced at 4 weeks postinjection of 79Q, and the
numbers of orexin neurons were reduced 18weeks postinjection (I–L). *p < 0.05 compared to 18Q and control. All data are expressed asmeans ± SEM. Scale bar
represents 200 mm.
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as a protein interacting with htt, and has been found highly
enriched in neurons particularly in the hypothalamus (Li et al.,
1995). Previous studies have shown that levels of HAP-1 are
reduced in transgenic HD mice that display weight loss (Li
et al., 2003) and that HAP-1 is an important regulator of early
postnatal feeding (Chan et al., 2002; Sheng et al., 2006), although
this function might not be retained in adult stage (Dragatsis et al.,
2004). We therefore investigated whether HAP-1 levels were
altered in the hypothalamus in the twomodels used in this study.
However, we found that the development of the metabolicCphenotype occurred in the absence of changes in hypothalamic
HAP-1 levels both in 2-month-old BACHD and WT mice, and
4 weeks after bilateral expression of htt853-79Q in the hypothal-
amus in WT mice (Figures 6E–6G).
Changes of Orexin and PVN Neuropeptide Levels
Are Linked to Mutant htt Expression
Transcriptional dysregulation is a hallmark in HD (Kuhn et al.,
2007). Hypothalami from mice expressing htt853-79Q or 18Q,
and control animals, were therefore analyzed 4 weeks post-
injection using quantitative RT-PCR. To rule out a generalell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc. 435
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of a number of candidate genes in several signaling cascades
involved in regulation of energy homeostasis. We found no alter-
ations in the mRNA levels of a number of genes that are all asso-
ciated with hypothalamic-induced obesity and metabolic
changes (Belgardt et al., 2009; Kleinridders et al., 2009; Unger
et al., 2007) (Table 1). In the hypothalamus, the orexigenic
agouti-related protein (AgRP) and neuropeptide Y (NPY) as well
as the anorexigenic POMC are expressed in first-order neurons
and are main regulators of body weight. Nonetheless, mRNA
levels ofNPY,AgRP, andPOMCwere unalteredbetweengroups.
A recent study has found functional suppression of the tran-
scription factor Brain2 (Brn2) in the hypothalamus of the R6/2
HD mouse model (Yamanaka et al., 2010). The R6/2 mouse is
the most commonly used transgenic HD mouse model that
expresses an N-terminal fragment of the mutant HD gene and
displays a fast progressive phenotype (Mangiarini et al., 1996).
Brn2 is a cofactor of single-minded 1 (Sim1), which regulates
the expression of oxytocin, vasopressin, and corticotropin-
releasing hormone (CRH) in the paraventricular nucleus (PVN)
of the hypothalamus. Although we detected no change in the
mRNA levels of Brn2 and Sim1, we found significantly reduced
levels of mRNA for the neuropeptides CRH, oxytocin, somato-
statin, and thyrotropin-releasing hormone (TRH) expressed in
mice injected with the 79Q variant compared to 18Q 4 weeks
postinjection (Table 1). mRNA levels of vasopressin and orexin
1 receptors were reduced in both 79Q and 18Q compared to
controls (Table 1). Moreover, mRNA levels of orexin were signif-
icantly downregulated in mice injected with the 79Q variant at
4 weeks of age (Figure 6H). There were reduced numbers of
orexin-immunopositive neurons at 18 weeks postinjection in
the 79Q variant compared to both the 18Q variant and uninjected
controls as assessed using stereology (Figures 6I–6L). Expres-
sion of 18Qmight had a subtle effect on orexin neurons, as there
was a trend for a reduced number in this group as compared to
uninjected controls, although this difference did not reach signif-
icance (p = 0.051). Taken together, this initial candidate-based
screen suggested that the primary factors inducing hyperphagia
and insulin resistance after 79Q injection involved reduced tran-
scription of PVN neuropeptides as well as reduced orexin levels.
DISCUSSION
Recent studies have described metabolic disturbances in HD
patients such as insulin resistance and increased caloric intake
(Lalic et al., 2008; Marder et al., 2009; Mochel et al., 2007). These
abnormalities could be due to hypothalamic dysfunction, and in
fact, other reports have suggested that hypothalamus is an
important site for pathology in clinical HD (Aziz et al., 2008;
Douaud et al., 2006; Gabery et al., 2010; Kassubek et al.,
2004; Petersen et al., 2005; Politis et al., 2008; Soneson et al.,
2010). However, experiments that establish a causal link
between selective expression of mutant htt in the hypothalamus
and metabolic abnormalities have not yet been reported. There-
fore, we designed the present study to test whether such a caus-
ative relationship exists. We began by characterizing in detail the
metabolic profile of the BACHD mice. We found that they devel-
oped metabolic disturbances with hyperphagic obesity in the
presence of systemic insulin and leptin resistance. The develop-436 Cell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc.ment of obesity with increased food intake in the absence of
increased levels of peripheral appetite-stimulating factors sug-
gested a centrally regulated phenotype, probably originating in
the hypothalamus, a key target of leptin and insulin.
To provide evidence that mutant htt expression in the hypo-
thalamus can lead to a metabolic phenotype, we expressed
two different fragments of mutant htt selectively in the hypothal-
amus of normal mice using rAAV vectors. Targeted expression in
the hypothalamus indeed led to increased food intake and rapid
and severe obesity on a normal diet, recapitulating the BACHD
phenotype. The experiments illustrated that hypothalamic
expression of both a short fragment and a longer fragment of
mutant htt, but not an equally sized htt fragment with a normal
polyglutamine length, caused increased body weight.
The size of the htt fragments was similar to what has been
published in a previous study using lentiviral vector delivery to
the striatum of rats (de Almeida et al., 2002). We chose the 853
amino acid fragment, as it contained many of the suggested
important sites for posttranslational modification (Imarisio
et al., 2008). In a subset of experiments, we used a smaller frag-
ment of 171 amino acids, as it was similar to the length of mutant
htt expressed in transgenicmicewhich developedweight loss (Li
et al., 2003; Mangiarini et al., 1996; Weydt et al., 2006) and
allowed us to demonstrate that expression of a very short frag-
ment of mutant htt in the hypothalamus also led to metabolic
dysfunction and surprisingly increased body weight.
The development of the metabolic phenotype in BACHD mice
could be prevented if mutant htt was inactivated in the hypothal-
amus at an early stage in female mice. However, if the metabolic
phenotype had developed, it could no longer be reversed by the
same mechanism that could prevent its onset. This finding is
interesting for several reasons: first, the fact that a certain pheno-
type in an HD mouse model can be reversed by inactivation of
mutant htt in the hypothalamus brings support for this region
to be important in the disease process. Second, our results indi-
cate that there may be a limited window of opportunity for effec-
tive therapeutic interventions aimed at correcting metabolic
dysfunction in HD, or other related conditions with hypothalamic
pathologies leading to obesity. It is plausible that the mecha-
nisms initiating a pathogenic process may be different than
those that maintain the diseased state or cause progression.
In the search for a therapeutic strategy for this fatal disease,
attempts have focused on silencing mutant htt in the striatum
and the cerebral cortex (Boudreau et al., 2009; DiFiglia et al.,
2007; Drouet et al., 2009). However, our results suggest that
silencingmutant htt also in other brain regions, such as the hypo-
thalamus, may prove to be important in order to interfere with the
pathogenesis and ameliorate all symptoms and signs. This idea
is also supported by a recent study showing positive effect on
both glucose homeostasis and neuropathology in another
animal model of HD using an antidiabetic glucagon-like peptide
1 receptor agonist that acts in the hypothalamus (Martin et al.,
2009). Furthermore, analyses of body weight and metabolic
parameters provide powerful readouts to study the effects of
therapeutic interventions aimed at correcting the metabolic
dysfunction of mutant htt both on molecular and systems levels.
Taken together, inhibiting the pathological effects of mutant htt
in the hypothalamus may indeed serve as a therapeutic target
for HD.
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leading to metabolic disturbances are activated by mutant htt
expression in the hypothalamus.We found that selective expres-
sion of a mutant htt fragment led to the formation of htt and ubiq-
uitinated inclusions in the neurons in the hypothalamus without
causing gliosis, microglia activation, or any immune reactions.
We therefore ruled out that the phenotype was caused by an
inflammatory reaction, which has been found to be involved in
diet-induced obesity (Belgardt et al., 2010; Kleinridders et al.,
2009; Zhang et al., 2008). Moreover, no overt neuronal loss
was detected in the hypothalamus in either BACHDmice or after
bilateral mutant htt expression, and hence, the obesity could not
be due to merely structural bilateral ventromedial lesions, known
to cause hyperphagic obesity (Hetherington and Ranson, 1942).
Also, the development of the metabolic phenotype was not
associated with changes in IGF-1 levels or HAP-1 expression,
two factors previously implicated in body weight changes in
HD animal models (Li et al., 2003; Pouladi et al., 2010).
We have also performed studies to investigate whether
htt853-79Q expression resulted in a general dysregulation of
hypothalamic circuits. We analyzed mRNA levels of a set of
candidate genes in different signaling cascades. Out of the
analyzed neuropeptide genes, we found that the initiation of
body weight gain 4 weeks after hypothalamic injections of
mutant htt was associated with reduced mRNA levels of several
neuropeptides in the PVN of the hypothalamus such as the
anorectic CRH, which may be involved in causing increased
appetite and obesity (Masaki et al., 2003). Alterations in neuro-
peptide levels in the PVN have recently been reported in the
humanHD hypothalamus (Gabery et al., 2010).We also detected
significantly reduced mRNA levels of orexin and reduced
numbers of orexin-immunopositive neurons after expression of
the 79Q variant. Interestingly, animal models with genetic abla-
tion of orexin develop obesity (Hara et al., 2001), and recent
studies indicate a role of orexin in regulating hypothalamic insulin
signaling and glucose homeostasis (Funato et al., 2009; Tsuneki
et al., 2008; Yi et al., 2009). As loss of orexin in the hypothalamus
and insulin resistance occur in HD patients (Aziz et al., 2008;
Gabery et al., 2010; Lalic et al., 2008; Petersen et al., 2005), it
is possible that the effects of mutant htt on the orexin system
are involved in causing the metabolic phenotype in HD. Further
studies are, however, needed to identify the exact mechanism
of mutant htt in the hypothalamus.
Although we have established a causative relationship
between expression of mutant htt expression in the hypothal-
amus and the development of a metabolic phenotype, it is still
unclear why some of the mouse models, including those we
studied here, become obese at an early time point, while HD
patients are known to display weight loss most notably in
advanced stages of the disease (Phillips et al., 2008). However,
it is important to note that the metabolic profile of HD gene
carriers especially in the prodromal period and early stages of
the disease is not fully known and needs further investigation.
Metabolic disturbances have been studied in HD animal models,
and interestingly, whereas several transgenic mice expressing
the N-terminal fragments of htt lose weight, other transgenic
mice expressing full-length mutant htt develop increased body
weight similar to BACHD mice (Bjorkqvist et al., 2006; Gray
et al., 2008; Li et al., 2003; Mangiarini et al., 1996; van derCBurg et al., 2008; Van Raamsdonk et al., 2006; Weydt et al.,
2006). Clearly, expression of mutant htt can cause metabolic
imbalance with both weight gain and weight loss as conse-
quences. The discrepancy in body weight between the different
animal models may be due to levels of mutant htt expression or
the stage in disease progression. Possibly, weight loss seen in
advanced HD patients andmousemodels resembling end-stage
disease is a result of peripheral effects of mutant htt.
In the YAC line, both mice ubiquitously overexpressing full-
lengthmutant htt with 128Q andmice overexpressing the normal
full-length htt with 18Q repeats develop obesity, whereas YAC
mice with a shorter fragment have normal body weight (Pouladi
et al., 2010; Van Raamsdonk et al., 2006). This finding is at vari-
ance with the results we obtained in the present study, in which
the expression of an 853 amino acid fragment of htt with 79Q
selectively in the hypothalamus led to increased body weight,
whereas the same expression level of the htt fragment with
18Q did not cause obesity. However, our findings of reduced
mRNA expression levels of vasopressin and orexin 1 receptor
together with effects on IGF-1 levels and explorative motor
activity at a later stage after overexpression of htt853-18Q
suggest that also WT htt might affect the metabolic pathways
in the hypothalamus.
A common feature among several of the mouse models inde-
pendently of body weight and length of mutant htt is accumula-
tion of body fat (Hult et al., 2010). The fact that this also occurs
after selective hypothalamic expression of mutant htt when there
is no expression of mutant htt in the periphery suggests that fat
accumulation can be triggered by hypothalamic dysfunction
induced by mutant htt. Furthermore, the features of insulin resis-
tance and increased food intake that developed as a result of
mutant htt expression in the hypothalamus have been found in
several of the other HDmodels, which also display hypothalamic
changes (Hult et al., 2010). Interestingly, whereas female and
male BACHD mice in general displayed a similar metabolic
phenotype, certain aspects such as the increase in body fat
and serum cholesterol levels were more pronounced in female
mice. These sex differences would be interesting to explore
further, including in clinical studies aimed at elucidating the
metabolic imbalance of HD in more detail.
In conclusion, our study provides evidence of a causal rela-
tionship between expression of mutant htt in the hypothalamus
andmetabolic disturbances. Our results indicate that expression
of mutant htt in the hypothalamus disrupts critical pathways in
control of food intake and body weight. Further insights into
how the molecular signaling affected by htt intersects with the
complex network regulating metabolism may shed light on the
disease mechanisms in HD and may open up new avenues for
therapeutic intervention.
EXPERIMENTAL PROCEDURES
The complete Experimental Procedures section can be found as online
supplementary material (see the Supplemental Experimental Procedures). A
brief experimental protocols description appears below.
Experimental Design and Animals
Two sets of experiments were carried out. In the first part, we characterized the
metabolic profile of the BACHD mice expressing full-length mutant htt with
97Q (Gray et al., 2008). Some of these mice were injected in the hypothalamusell Metabolism 13, 428–439, April 6, 2011 ª2011 Elsevier Inc. 437
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mutant htt gene. In the second set of experiments, WT mice from the same
FVB/N strain were injected in the hypothalamus with rAAV5 vectors coding
for htt fragments with either 18Q or 79Q (de Almeida et al., 2002). A group of
mice injected with rAAV5-GFP was used to illustrate transduction efficiency.
Metabolic Analyses
Mice were analyzed using measurements of body weight, food intake, fat
content, and general motor activity. GTT and ITT were performed using i.p.
injections of glucose or insulin after a 4 hr fast. Indirect calorimetric measure-
ments were performed during 21 hr using the Somedic INCA system. Serum
levels of metabolic factors were measured using ELISA or radioimmunoassay
kits.
Postmortem Analyses
Stereological estimation of number of neurons and glia, different immunopos-
itive cells including cells displaying htt- or ubiquitin-positive inclusions, or Cre
expression in the hypothalamic region were performed by applying the optical
fractionator principle (West, 1999). Confocal microscopical analysis was done
to characterize the phenotype of transduced neurons. mRNA expression or
protein expression was analyzed using quantitative RT-PCR or western blots
from hypothalami dissected from mice 4 weeks after bilateral injections of
the htt fragments as well as from uninjected mice.
Statistical Analyses
Statistical analyses were performed using SPSS 18 statistical package (SPSS
Inc. Chicago, IL). One- or two-way ANOVA followed by appropriate post hoc
analysis was performed to determine the statistically significant differences
(set at p < 0.05). Data are presented as mean ± SEM. See the Supplemental
Statistical Results section in the Supplemental Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, six tables, Supplemental
Experimental Procedures, Supplemental References, and Supplemental
Statistical Results and can be found with this article at doi:10.1016/j.cmet.
2011.02.013.
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